MX2019003908A - Metodo por multiproteasa. - Google Patents

Metodo por multiproteasa.

Info

Publication number
MX2019003908A
MX2019003908A MX2019003908A MX2019003908A MX2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A
Authority
MX
Mexico
Prior art keywords
methods
protease
proteases
protein
combination
Prior art date
Application number
MX2019003908A
Other languages
English (en)
Inventor
Trkulja Carolina
Orwar Owe
Davidson Max
Hägglund Jessica
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2019003908A publication Critical patent/MX2019003908A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Abstract

La presente invención se refiere a métodos para identificar un epítope en una proteína que se puede unir por un anticuerpo. Los métodos de la invención normalmente implican una etapa de proteólisis limitada o restringida de una proteína utilizando una única primera proteasa o una combinación de primeras proteasas, y una etapa de proteólisis adicional mediante el uso de una única segunda proteasa o una combinación de segundas proteasas. La invención también se refiere a epítopes identificados y a anticuerpos que se unen a epítopes que han sido identificados mediante los métodos de la invención.
MX2019003908A 2016-10-06 2017-10-06 Metodo por multiproteasa. MX2019003908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617002.9A GB201617002D0 (en) 2016-10-06 2016-10-06 Multi-protease method
PCT/EP2017/075532 WO2018065599A1 (en) 2016-10-06 2017-10-06 Multi-protease method

Publications (1)

Publication Number Publication Date
MX2019003908A true MX2019003908A (es) 2019-06-10

Family

ID=57610568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003908A MX2019003908A (es) 2016-10-06 2017-10-06 Metodo por multiproteasa.

Country Status (14)

Country Link
US (1) US11408883B2 (es)
EP (1) EP3523659A1 (es)
JP (1) JP7046931B2 (es)
KR (1) KR102411384B1 (es)
CN (1) CN109891247B (es)
AU (1) AU2017339096B2 (es)
BR (1) BR112019006624A2 (es)
CA (1) CA3039064A1 (es)
GB (1) GB201617002D0 (es)
IL (1) IL265612B2 (es)
MA (1) MA46454A (es)
MX (1) MX2019003908A (es)
NZ (1) NZ752437A (es)
WO (1) WO2018065599A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN114853855B (zh) * 2022-04-14 2023-06-20 安徽省华信生物药业股份有限公司 一种具有促降血糖激素glp-1分泌作用的富铬酵母活性肽

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2179036T3 (es) 1990-10-18 2003-01-16 Cancerforskningsfonden Af 1989 .nticuerpos contra el receptor uroquinasa y su uso
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
US7939295B2 (en) 2001-07-13 2011-05-10 Merck Patent Gmbh Methods for reducing immunogenicity of polypeptides
US7632686B2 (en) 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
WO2004031730A2 (en) 2002-10-03 2004-04-15 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
WO2006005472A1 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)
US20060292639A1 (en) 2004-08-13 2006-12-28 Adolor Corporation Splice variant of the vanilloid receptor VR1A
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
SE0403139D0 (sv) 2004-12-23 2004-12-23 Nanoxis Ab Device and use thereof
JP2008175814A (ja) 2006-12-21 2008-07-31 Eisai R & D Management Co Ltd 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット
JP5555846B2 (ja) 2007-03-30 2014-07-23 国立大学法人山口大学 急性中枢神経障害の予後判定方法
KR101649189B1 (ko) 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
US20120128646A1 (en) * 2009-02-17 2012-05-24 Kathryn Haskins Methods and compositions for the treatment of autoimmune disease
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US9383367B1 (en) 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
WO2013020557A1 (en) * 2011-08-08 2013-02-14 Syddansk Universitet Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination
MA41842A (fr) * 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope

Also Published As

Publication number Publication date
AU2017339096B2 (en) 2023-03-30
IL265612B2 (en) 2024-04-01
KR102411384B1 (ko) 2022-06-20
CN109891247A (zh) 2019-06-14
US11408883B2 (en) 2022-08-09
GB201617002D0 (en) 2016-11-23
CN109891247B (zh) 2022-10-04
US20200041499A1 (en) 2020-02-06
JP7046931B2 (ja) 2022-04-04
RU2019108573A3 (es) 2021-01-21
WO2018065599A1 (en) 2018-04-12
NZ752437A (en) 2022-12-23
KR20190062504A (ko) 2019-06-05
MA46454A (fr) 2019-08-14
RU2019108573A (ru) 2020-11-06
CA3039064A1 (en) 2018-04-12
IL265612B1 (en) 2023-12-01
IL265612A (en) 2019-05-30
EP3523659A1 (en) 2019-08-14
JP2020502482A (ja) 2020-01-23
AU2017339096A1 (en) 2019-05-02
BR112019006624A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2019008146A (es) Virus alterado.
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
MY195993A (en) Antibodies and Antibody Fragments for Site-Specific Conjugation
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
WO2018035084A8 (en) Monovalent asymmetric tandem fab bispecific antibodies
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
TN2016000525A1 (en) Tri-specific binding molecules and methods of use thereof
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
NZ735823A (en) New methods for epitope selection
AR105267A1 (es) Anticuerpos de unión a tau
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
PH12019502298A1 (en) Monoclonal antibody to pd-l1
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
CU24556B1 (es) Anticuerpos anti-basigin humanizados
MX2019003908A (es) Metodo por multiproteasa.
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
WO2013115410A3 (en) Anti-phospholipase d4 antibody
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
MX2019002455A (es) Metodos para la identificacion de epitopes.